Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
The US International Trade Commission (ITC) upheld its preliminary ruling saying that South Korean drugmaker Daewoong Pharmaceutical Co. copied the manufacturing process of a botulinum toxin strain by local rival Medytox Inc. in Medytox Medytox
Consequently, the US trade panel ordered a 21-month ban on imports of Daewoong Pharmaceutical's botulinum products into the US.
ITC's ruling, however, reduces the initial 10-year ban prescribed by the preliminary panel that ruled that Daewoong's misappropriated trade secrets belonging to Medytox.
Medytox Inc. claimed that Daewoong's Jeuveau was developed using a trade secret stolen from it that turns the deadly botulinum toxin into a wrinkle treatment.
Daewoong denied any theft allegations or that any trade secret was involved and argued the US agency is not the proper forum to decide on the dispute.
